Ann H Partridge1, Melissa E Hughes2, Erica T Warner2, Rebecca A Ottesen2, Yu-Ning Wong2, Stephen B Edge2, Richard L Theriault2, Douglas W Blayney2, Joyce C Niland2, Eric P Winer2, Jane C Weeks2, Rulla M Tamimi2. 1. Ann H. Partridge, Melissa E. Hughes, Erica T. Warner, Eric P. Winer, Jane C. Weeks, and Rulla M. Tamimi, Dana-Farber Cancer Institute and Brigham and Women's Hospital; Erica T. Warner, Harvard T.H. Chan School of Public Health, Boston, MA; Rebecca A. Ottesen and Joyce C. Niland, City of Hope Comprehensive Cancer Center, Duarte; and Douglas W. Blayney, Stanford Cancer Institute, Palo Alto, CA; Yu-Ning Wong, Fox Chase Cancer Center, Philadelphia, PA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; and Richard L. Theriault, The University of Texas MD Anderson Cancer Center, Houston, TX. ahpartridge@partners.org. 2. Ann H. Partridge, Melissa E. Hughes, Erica T. Warner, Eric P. Winer, Jane C. Weeks, and Rulla M. Tamimi, Dana-Farber Cancer Institute and Brigham and Women's Hospital; Erica T. Warner, Harvard T.H. Chan School of Public Health, Boston, MA; Rebecca A. Ottesen and Joyce C. Niland, City of Hope Comprehensive Cancer Center, Duarte; and Douglas W. Blayney, Stanford Cancer Institute, Palo Alto, CA; Yu-Ning Wong, Fox Chase Cancer Center, Philadelphia, PA; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; and Richard L. Theriault, The University of Texas MD Anderson Cancer Center, Houston, TX.
Abstract
PURPOSE: Young women are at increased risk for developing more aggressive subtypes of breast cancer. Although previous studies have shown a higher risk of breast cancer recurrence and death among young women with early-stage breast cancer, they have not adequately addressed the role of tumor subtype in outcomes. METHODS: We examined data from women with newly diagnosed stage I to III breast cancer presenting to one of eight National Comprehensive Cancer Network centers between January 2000 and December 2007. Multivariable Cox proportional hazards models were used to assess the relationship between age and breast cancer-specific survival. RESULTS: A total of 17,575 women with stage I to III breast cancer were eligible for analysis, among whom 1,916 were ≤ 40 years of age at diagnosis. Median follow-up time was 6.4 years. In a multivariable Cox proportional hazards model controlling for sociodemographic, disease, and treatment characteristics, women ≤ 40 years of age at diagnosis had greater breast cancer mortality (hazard ratio [HR], 1.4; 95% CI, 1.2 to 1.7). In stratified analyses, age ≤ 40 years was associated with statistically significant increases in risk of breast cancer death among women with luminal A (HR, 2.1; 95% CI, 1.4 to 3.2) and luminal B (HR 1.4; 95% CI, 1.1 to 1.9) tumors, with borderline significance among women with triple-negative tumors (HR, 1.4; 95% CI, 1.0 to 1.8) but not among those with human epidermal growth factor receptor 2 subtypes (HR, 1.2; 95% CI, 0.8 to 1.9). In an additional model controlling for detection method, young age was associated with significantly increased risk of breast cancer death only among women with luminal A tumors. CONCLUSION: The effect of age on survival of women with early breast cancer seems to vary by breast cancer subtype. Young age seems to be particularly prognostic in women with luminal breast cancers.
PURPOSE: Young women are at increased risk for developing more aggressive subtypes of breast cancer. Although previous studies have shown a higher risk of breast cancer recurrence and death among young women with early-stage breast cancer, they have not adequately addressed the role of tumor subtype in outcomes. METHODS: We examined data from women with newly diagnosed stage I to III breast cancer presenting to one of eight National Comprehensive Cancer Network centers between January 2000 and December 2007. Multivariable Cox proportional hazards models were used to assess the relationship between age and breast cancer-specific survival. RESULTS: A total of 17,575 women with stage I to III breast cancer were eligible for analysis, among whom 1,916 were ≤ 40 years of age at diagnosis. Median follow-up time was 6.4 years. In a multivariable Cox proportional hazards model controlling for sociodemographic, disease, and treatment characteristics, women ≤ 40 years of age at diagnosis had greater breast cancer mortality (hazard ratio [HR], 1.4; 95% CI, 1.2 to 1.7). In stratified analyses, age ≤ 40 years was associated with statistically significant increases in risk of breast cancer death among women with luminal A (HR, 2.1; 95% CI, 1.4 to 3.2) and luminal B (HR 1.4; 95% CI, 1.1 to 1.9) tumors, with borderline significance among women with triple-negative tumors (HR, 1.4; 95% CI, 1.0 to 1.8) but not among those with humanepidermal growth factor receptor 2 subtypes (HR, 1.2; 95% CI, 0.8 to 1.9). In an additional model controlling for detection method, young age was associated with significantly increased risk of breast cancer death only among women with luminal A tumors. CONCLUSION: The effect of age on survival of women with early breast cancer seems to vary by breast cancer subtype. Young age seems to be particularly prognostic in women with luminal breast cancers.
Authors: Silvia Gisiger-Camata; Timiya S Nolan; Jacqueline B Vo; Jennifer R Bail; Kayla A Lewis; Karen Meneses Journal: J Cancer Educ Date: 2019-04 Impact factor: 2.037
Authors: Ciara C O'Sullivan; Sheeba Irshad; Zheyu Wang; Zhuojun Tang; Christopher Umbricht; Gary L Rosner; Mindy S Christianson; Vered Stearns; Karen Lisa Smith Journal: Breast Cancer Res Treat Date: 2020-03-11 Impact factor: 4.872
Authors: Alexandra Thomas; Anthony Rhoads; Jonathan Suhl; Kristin M Conway; William G Hundley; Lacey R McNally; Jacob Oleson; Susan A Melin; Charles F Lynch; Paul A Romitti Journal: Clin Breast Cancer Date: 2020-02-04 Impact factor: 3.225
Authors: Rachel A Freedman; Nancy L Keating; Nancy U Lin; Eric P Winer; Ines Vaz-Luis; Joyce Lii; Pedro Exman; William T Barry Journal: Cancer Date: 2018-03-02 Impact factor: 6.860
Authors: V Zenzola; M A Cabezas-Quintario; M Arguelles; E Pérez-Fernández; Y Izarzugaza; A Correa; J García-Foncillas Journal: Clin Transl Oncol Date: 2018-04-18 Impact factor: 3.405